Kyleena Intrauterine Device
NDC Package 50419-424-08
Package Information
Kyleena (levonorgestrel) intrauterine devices is kyleena is indicated to prevent pregnancy for up to 5 years. This formulation utilizes a intrauterine device delivery system. Marketed by Bayer Healthcare Pharmaceuticals Inc., this product is identified by NDC 50419-424 and is authorized under FDA application NDA208224.
Identification & Billing
- RxCUI: 1811886 - levonorgestrel 19.5 MG Intrauterine System
- RxCUI: 1811886 - levonorgestrel 0.000729 MG/HR Intrauterine System
- RxCUI: 1811886 - levonorgestrel 17.5 MCG per 24 HR Intrauterine System
- RxCUI: 1856546 - Kyleena 19.5 MG Intrauterine System
- RxCUI: 1856546 - levonorgestrel 0.000729 MG/HR Intrauterine System [Kyleena]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50419 - Bayer Healthcare Pharmaceuticals Inc.
- 50419-424 - Kyleena
- 50419-424-08 - 1 INTRAUTERINE DEVICE in 1 CARTON
- 50419-424 - Kyleena
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (50419-424). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50419-424-08 identifies a specific commercial package of 1 intrauterine device in 1 carton of Kyleena, a human prescription drug labeled by Bayer Healthcare Pharmaceuticals Inc.. This intrauterine device is formulated for intrauterine use and contains levonorgestrel as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bayer Healthcare Pharmaceuticals Inc. on September 19, 2016. The current certification is valid through December 31, 2026.
How is this Bayer Healthcare Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50419042408. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.